Isis preclinical data

ISIP published animal results with its antisense blocker of PKC-alpha, a signal transducer protein that regulates cell growth. The agent, which is in Phase I testing, blocked growth in three different tumor cell lines in a dose-dependent and sequence-dependent manner, as reported in Cancer Research.

The antisense agent slowed or stopped the division of cells from three tumor lines, implanted in nude mice, by reducing expression of the PKC-alpha mRNA. Repeated doses of the drug could be administered, at levels at least 100-fold higher than that required for suppression of PKC-alpha, with little toxicity. ...